Applied DNA Receives Kosher Certification from Orthodox Union for Qualifying Products

Products within the SigNature^® and CertainT^® Brand Certified in Strict Compliance with OU Standards as Ingredients for Dietary Supplements, Pharmaceuticals and Food Products

STONY BROOK, N.Y.–(BUSINESS WIRE)–$apdn #anticounterfeiting—Applied DNA Sciences, Inc. (“Applied DNA”, the “Company”, NASDAQ: APDN), announced receipt of certification from the Orthodox Union (OU^®) for products within the SigNature and CertainT line following a thorough evaluation of the Company’s products and manufacturing processes. The Pareve kosher designation will first be used for the Nutrition21 Nitrosigine^® sports supplement product recently announced. The Company’s products and services, used by its customers to manage traceability and authenticity in the name of brand assurance, are also suitable for related markets such as food and pharmaceuticals.

The OU (Orthodox Union) Kosher is the world’s largest and most widely recognized international kosher certification agency, certifying over 800,000 products produced in more than 9,011 plants located in 104 countries around the world. Over $150 billion of kosher certified products are consumed annually, with the OU kosher symbol appearing on close to 70% of America’s kosher certified foods.

“As we grow our presence in food, pharmaceutical and dietary supplements markets, we are pleased to be supportive of the business imperatives critical to meet market requirements that maximize adoption. We are proud to have the OU certification on our qualifying products. OU maintains strict guidelines for certification and ongoing manufacturing, marketing and distribution of products, making Applied DNA’s mission for enabling our customers a platform for proof of authenticity and traceability nicely complementary for OU-certified products,” said Dr. James Hayward, president and CEO, Applied DNA.

The Company’s qualifying CertainT and SigNature molecular tags enable companies and their supply chains to designate a unique molecular identity to products with meaning specific to the tagged material: for example, geographic facility location, brand, product line or date of manufacture. This tag can be blended into ingredients and packaging inks and varnishes in the pharmaceutical, nutraceutical, and dietary supplements industry. The tag enables its carrier to be verified for authenticity and blending detection, either at the customer or in the Applied DNA laboratory, depending on application requirements.

“Applied DNA Sciences is leading the way in supply chain authentication,” commented Rabbi Menachem Genack, CEO, OU Kosher, “and we are excited to partner with them as they expand into the market of dietary supplements, food ingredients and nutraceuticals. In turn,” he observed, “their molecular tag offers our supervision program an additional instrument for validating the integrity of our certified products.”

About Applied DNA Sciences

Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN.

Forward-Looking Statements

The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our ability to successfully enter into commercial contracts for the implementation of our CertainT^® platform, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, the Company’s history of net losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 12, 2019 and our subsequent quarterly report on Form 10-Q filed on February 6, 2020, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contacts

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, [email protected]
program contacts: Judy Murrah, Chief Information Officer, 631-240-8819, [email protected]
web: www.adnas.com
twitter: @APDN